Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril 2013 Sep;100(3):638-44
Date
07/16/2013Pubmed ID
23849842DOI
10.1016/j.fertnstert.2013.06.013Scopus ID
2-s2.0-84883444909 (requires institutional sign-in at Scopus site) 157 CitationsAbstract
Methotrexate, a folic acid antagonist, is an effective treatment for early unruptured ectopic pregnancy. Several treatment regimens are available. Methotrexate is more effective when used to treat ectopic pregnancies with lower human chorionic gonadotropin (hCG) levels. However, there is no consensus on a threshold value that best predicts success or failure. Methotrexate can be used to treat ectopic pregnancies that occur in cornual, cervical, and cesarean scar locations, and it does not adversely affect ovarian reserve or subsequent fertility. This document replaces the previous document of the same name, last published in 2008 (Fertil Steril 2008;90:S206-12).
Author List
Practice Committee of American Society for Reproductive MedicineAuthor
Jay I. Sandlow MD Chair, Professor in the Urologic Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Abortifacient AgentsAbortion, Induced
Costs and Cost Analysis
Female
Folic Acid Antagonists
Humans
Methotrexate
Pregnancy
Pregnancy, Ectopic
Prevalence
Risk Factors
Treatment Outcome